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Precision oncology is expected to improve outcome ofpatients with malignant diseases by taking intoaccount individual variability.1 This approach is
strictly linked to the availability of a targeted treatment
the efficacy of which depends on the presence of a molec-
ular alteration, i.e., a predictive biomarker. This concept
has been shown to be highly successful in well-defined
subgroups of patients and has led to the histology-agnos-
tic approval of drugs in solid tumors.2 Biomarker-stratified
treatment has become first-line treatment in several solid
tumors, such as non-small cell lung cancer. In many
hematopoietic malignancies, including B-cell lymphomas,
comparably higher cure rates and more treatment options
have led to a more prognosis-oriented stratification of
treatment. Here, prognostic biomarkers help to adjust
treatment intensity to a cohort risk assessment.3 Together
with improved prognostication of patients, a more refined
diagnosis also helps with better treatment allocation.
Therefore, diagnostic biomarkers will help with the iden-
tification of defined disease subgroups.4 This might also
correspond to differential outcome and/or response to
treatment, and can therefore overlap with predictive
and/or prognostic markers. 
However, despite numerous advances in the under-
standing of cancer heterogeneity, not all diagnostic or
prognostic stratifications will ultimately impact treatment
and a number of patients will eventually have disease
recurrence or progression. Therefore, the identification of
novel treatment strategies is urgently required. The devel-
opment of additional predictive biomarkers and corre-
sponding drugs promises to improve outcome and limit
toxicity. This advancement of precision oncology can be
achieved in at least two ways: (i) the identification of the
right treatment for given patients (as often tried in umbrel-
la or unstratified precision oncology trials);5 or (ii) the
identification of the right patient for a given treatment (as
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usually tried in basket trials).2
In this issue of Haematologica, Gaudio et al. show the
efficacy of an antibody drug conjugate (ADC) targeting
CD205 in lymphoma models.6 Importantly, the efficacy of
this new drug, MEN1309/OBT076, was significantly asso-
ciated with cell surface expression of the target CD205 in
B-cell lymphoma cell lines. Furthermore, cytotoxicity of
MEN1309/OBT076 was reduced with the introduction of
a competitive CD205 antibody. These findings underline
the dependence of drug efficacy on target availability, sug-
gesting the potential of CD205 expression as a predictive
biomarker. In an in vitro screen, MEN1309/OBT076 effica-
cy did not depend on B-cell lymphoma subtype. Together
with previous preclinical results in CD205-positive triple-
negative breast, pancreatic and bladder cancer cell lines
and xenografts,7 this creates a virtual preclinical basket
trial which now awaits clinical validation. 
However, several questions remain to be answered for
the clinical development of MEN1309/OBT076 in lym-
phoma. In addition to its predictive significance in preclin-
ical models (that, as we have said, still needs to be validat-
ed in clinical trials), the biological function of CD205 is
surprisingly unclear. Previous reports show that CD205 is
expressed on leukocytes, mainly dendritic cells and mono-
cytes8,9 with a role in endocytosis and the recognition of
apoptotic and necrotic cells.10,11 The role in lymphomagen-
esis remains even less understood. A fusion protein
involving CD205 was identified in Hodgkin lymphoma12
but also in normal dendritic cell maturation.10 However,
improved characterization of the biological role of this
protein remains vital to understanding its implications in
the clinic (as a prognostic biomarker in the identification
of adequate clinical settings for the introduction of a novel
drug) as well as a diagnostic biomarker. If CD205 helps in
defining a biologically distinct subgroup within lym-
phomas, this would be particularly relevant for the identi-
fication of rational combination partners, of which two,
venetoclax and rituximab, showed promising signals in
the study by Gaudio et al.6 However, the broad expression
of the antigen with a moderate to intense CD205 expres-
sion in 20-50% of tested lymphoma samples, and an over-
all expression of the antigen in more than 70% of samples,
makes it unlikely that CD205 adequately reflects lym-
phoma heterogeneity, and stability of CD205 protein
expression needs to be validated. Stable expression of the
antigen is probably linked to continued efficacy of the
drug, following the successful examples of other ADC
such as brentuximab vedotin (targeting CD30),13
polatuzumab vedotin (targeting CD79b),14 or trastuzumab
emtansine (targeting HER2).15 Efficacy of trastuzumab
emtansine could still be demonstrated despite previous
HER2-directed therapies and retreatment with brentux-
imab vedotin showed responses in the majority of
patients that had relapsed after initial response to the
same drug.16 In the work by Gaudio et al.,6 a rechallenge
with MEN1309/OBT076 was also sufficient to induce
remission in the only xenograft model with tumor
regrowth after a first dose of the ADC. These and other
data support the further development of ADC as powerful
tools for the targeted delivery of cytotoxic drugs.
Interestingly, neither resistance to CD30-directed ADC or
to HER2-directed ADC seems to be mediated by a loss of
target antigen expression but rather by dysfunctional
intracellular metabolism of the payload.17,18 Again, the con-
tinued expression of CD205 even under therapeutic pres-
sure remains to be determined and is probably linked to
its biological role. Expression of the antigen is also impor-
tant to predict toxicities in human trials. Even though pre-
vious work has not identified relevant toxicities in
cynomolgus monkeys,7 potential risks to humans will also
depend on disease characteristics and are still  to be deter-
mined in ongoing clinical trials. 
Figure 1. On- and off-target toxicities from antibody-drug conjugates (ADC) within the lymphoma microenvironment. (A) Schematic ADC, consisting of an antibody, a
linker and the cytotoxic payload. Endocytosis of the ADC and linker cleavage will release the payload, resulting in cytotoxic effects. (B) On- and off-target cytotoxic effects
from payload release with or without ADC internalization in a tumor microenvironment with abundant but heterogeneous expression of the target antigen. Payloads might
be cleaved without endocytosis and/or permeate cell membranes to be taken up by bystander cells, thus facilitating drug efficacy even in tumor cells without adequate
antigen expression. Toxic effects from microtubule-targeted compounds like maytansine on non-proliferating cells are typically reduced as compared to highly prolifer-
ating malignant cells (blue) with activated cell cycle checkpoints.
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Since CD205 is broadly expressed in lymphoma cells
and leukocytes, target antigen expression can be expected
in most tumors and/or their microenvironment. Since
MEN1309/OBT076 is designed with a cleavable linker,
payload release does not necessarily depend on ADC
endocytosis, thus facilitating bystander killing and off-tar-
get toxicity.19 In the case of a broadly CD205 expressing
tumor microenvironment, an adequate on-tumor efficacy
could therefore be expected even without adequate on-
target effects and ubiquitous antigen expression on lym-
phoma cells (Figure 1). In this case, the novel ADC could
rather act as a more sophisticated chemotherapy-delivery
system and CD205 expression will not allow adequate
patient selection. Even in this case, the drug might still
prove useful in lymphoma therapy alone or in combina-
tion. However, the integration of this novel agent into cur-
rent treatment schedules might become more difficult.
In conclusion, the work by Gaudio et al.6 shows the
activity of the anti-CD205 ADC MEN1309/OBT076 in
preclinical CD205-positive lymphoma models that war-
rants further clinical investigation. The development of a
biomarker-drug combination allows for a targeted applica-
tion of this drug in clinical trials. However, additional pre-
clinical and translational work is required to shed light on
the role of CD205 in lymphomagenesis. This is important
for the rational development of this treatment as
monotherapy, but also, and in particular, as a part of com-
bination therapy. ADC continue to be important compo-
nents of tumor therapy that could sometimes find a place
between precision oncology and refined chemotherapy.
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